Europe
Medigene AG announced that its Supervisory Board has appointed Axel-Sven Malkomes as Chief Financial Officer and Chief Business Development Officer effective 1 April 2019.
Aurealis Pharma, a private biopharmaceutical company developing novel three-in-one combination biologics for chronic non-healing wounds and cancer announced 7.8MCHF funding provided by Swiss and foreign private investors, Finnvera plc, and Business Finland – the Finnish Innovation Funding Agency.
MDxHealth SA, announced that it received on February 7, 2019 the following notification of significant shareholdings in accordance with the Belgian Act of May 2, 2007 on the disclosure of important participations in issuers of which shares are admitted to trading on a regulated market and regarding miscellaneous provisions.
Auris Medical Holding AG announced its receipt of notice from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company did not meet Nasdaq’s January 28, 2019 deadline to regain compliance with Nasdaq Listing Rule 5550(a)(2) due to the bid price per share for its common shares remaining below $1.00.
Medtronic plc announced that it will report financial results for the third quarter of fiscal year 2019 on Tuesday, February 19 , 2019.
San Diego-based Arcturus Therapeutics announced it was reassuming 100 percent of its global rights for ARCT-810, a messenger RNA (mRNA) drug to treat OTC Deficiency. The drug previously had a 50/50 collaboration between Arcturus and Tubingen, Germany-based CureVac AG.
Based in Lexington, Mass. and Amsterdam, The Netherlands, uniQure updated its Phase IIb trial of AMT-061 in hemophilia B. AMT-061 is an AAV5-based gene therapy that contains a FIX-Padua variant, meaning a patent-protected form of Factor IX, the missing or insufficient protein that results in the disease.
Approval Based on Clinical Data from the PREMIER Trial - New Indication Provides Options for Patients with Small or Medium, Wide-Necked Brain Aneurysms
Health cluster outlined main objectives during annual event, which gathered more than 200 stakeholders: Medicen will focus on European and international development as well as development of the French precision medicine industry
Ongoing proof-of-concept trial AdrenOSS-II testing Adrecizumab in early septic shock
PRESS RELEASES